Validation that means something
Real product-market fit, assessed by the physicians who will actually use your technology, across volumes, geographies, and practice types.
We partner with founders from the earliest stages by providing physician insight, strategic guidance, disciplined capital, and an ecosystem designed to help build exceptional cardiovascular companies and create long-term enterprise value.
Real product-market fit, assessed by the physicians who will actually use your technology, across volumes, geographies, and practice types.
We help identify stronger commercialization pathways, new indications, and positioning, which often surfaces value the original team did not see.
A national cardiology and electrophysiology network, plus established relationships with the major cardiovascular strategics.
We map the route to strategic value from the first day, so the company is pointed toward the outcome rather than just the next round.
What it looks like when specialist physicians are in the work from the first decision.
vMap, an FDA‑cleared platform that maps arrhythmias non‑invasively from a standard 12‑lead ECG. NuPulse physicians led clinical diligence and syndicated the investment, and the electrophysiologists who evaluated the technology are the same specialists whose workflows it serves.
“NuPulse has been an exceptional partner well beyond their investment, bringing deep cardiology expertise and strategic perspective. Their team has served as a trusted sounding board, helping us validate critical decisions, strengthen key industry relationships, and provide thoughtful guidance as we’ve continued to scale and advance our mission.” Rob Krummen · Chief Executive Officer, Vektor Medical
Additional founder stories will be shared here as our portfolio companies make their own announcements. If you are building in cardiovascular or electrophysiology medtech, we would like to hear from you.
Three short steps, plain English. We do not sign NDAs prior to an initial review, so please share only non-confidential information. Every submission is read.
Non-confidential information only. Submissions receive an initial review by the NuPulse team and physician network. Submission does not constitute an offer of securities.